Quantcast
Last updated on April 16, 2014 at 6:35 EDT

Latest Peyronie's disease Stories

2014-04-14 12:32:51

Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These...

2014-04-08 04:22:15

2014: The Year of Innovation in Men's Health, According to New York Urology Specialists NEW YORK, April 8, 2014 /PRNewswire/ -- Men have lower life expectancy than women. This discrepancy is especially pronounced for African American men who live 6 fewer years than women. According to the CDC, life expectancy in the US is 76 years for men compared to 81 for women. http://photos.prnewswire.com/prnvar/20140408/NY00250LOGO Over the past 25 years, care for diseases that affect women...

2014-04-07 08:29:11

STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture...

2014-04-04 16:22:04

Also in This Edition: Jobs for Writers and Media Industry Blog Posts NEW YORK, April 4, 2014 /PRNewswire/ -- Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. If you are interested in interviewing any of the experts, please contact them via the contact information at the end of the listing. To receive these updates by email, send a note to profnet@profnet.com with the industries you cover, and we'll add you to the appropriate...

2014-03-12 23:23:25

After more than a decade of short-term cures for erectile dysfunction, most aimed at symptoms rather than the underlying issues of nerve, muscle and blood vessel damage, a new approach has emerged from adult stem cell technology developed by the DaSilva Institute, that offers hope for erectile dysfunction treatment. Sarasota, FL (PRWEB) March 12, 2014 Erectile dysfunction (ED) is the most commonly studied disorder when it comes to male sexual dysfunction. It is estimated that 18 million...

2014-03-06 08:31:26

LYNBROOK, N.Y., March 6, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2013 and provided a corporate update. "2013 was a very productive and momentous year for BioSpecifics as we continued to demonstrate the vast potential of injectable...

2014-03-04 08:31:02

CHESTERBROOK, Pa., March 4, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET...

2014-02-27 08:30:09

LYNBROOK, N.Y., Feb. 27, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, today announced that it will host a conference call and live audio webcast at 8:30 a.m. EST on Thursday, March 6, 2014 to report its fourth quarter and full year 2013 financial results and provide a corporate update. In order to participate in the...

2014-02-25 08:30:54

CHESTERBROOK, Pa., Feb. 25, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Cowen and Company 34(th) Annual Healthcare Conference to be held March 3-5, 2014 at the Boston Marriott Copley Place Hotel in Boston. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and...

2014-02-24 08:27:24

PDUFA Date Scheduled for October 20, 2014 CHESTERBROOK, Pa., Feb. 24, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's submission of a supplemental Biologics License Application (sBLA) requesting approval of XIAFLEX (collagenase clostridium histolyticum, or CCH) for the treatment of two Dupuytren's contracture (DC)...